Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
Living with severe depression or an anxiety disorder can have a similar impact on patients’ promptness in seeking care following an HIV diagnosis as living far […]
Study finds more than 80 percent of patients needing WHO recommended last resort treatment for drug-resistant TB not getting it
Roughly four years after the World Health Organization recommended that the newest drugs against tuberculosis be made available to patients for whom they represented a last […]
WHO report on global antibiotic resistance highlights growing threats in the face of surveillance gaps
Surveillance data from 22 countries show some of the world’s most common and potentially deadly infections gaining ground globally against the antibiotics used to treat them, […]
The idea of pairing responses to diseases found in the global south that are so neglected that they are classified by that word with the better-funded, […]